Vera Therapeutics Shares Climb 14% on Positive Results in Kidney Disease Study

Dow Jones

Oct 28, 2024

By Jasmine Li

Shares of Vera Therapeutics rose after trial results for its atacicept treatment showed potential to prevent kidney failure in patients with immunoglobulin A nephropathy.

The biotechnology company's stock climbed 14.18% in Monday morning trading. Shares have more than quadrupled year over year.

Brisbane, Calif.-based Vera Therapeutics said Saturday evening the phase 2b trial showed stabilized kidney function through 96 weeks of long-term follow-up in patients with the chronic kidney disease that occurs when the protein IgA builds up in the kidneys.

"The stabilization of kidney function through two years -- the longest duration of data among B cell modulators to date -- positions atacicept as a potential best- and first-in-class treatment option for patients with IgAN," said Chief Executive Marshall Fordyce.

Fordyce said the company plans to announce topline results from the phase 3 trial in the second quarter of 2025, and apply for a biologics license application from the Food and Drug Administration later in the year.

Write to Jasmine Li at jasmine.li@wsj.com

(END) Dow Jones Newswires

October 28, 2024 10:31 ET (14:31 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2478482623"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2478482623\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2478482623?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-28 22:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2478482623","market":"fut","top_or_hot":-1,"title":"Vera Therapeutics Shares Climb 14% on Positive Results in Kidney Disease Study","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Jasmine Li \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of Vera <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> rose after trial results for its atacicept treatment showed potential to prevent kidney failure in patients with immunoglobulin A nephropathy. \n</p>\n<p>\n  The biotechnology company's stock climbed 14.18% in Monday morning trading. Shares have more than quadrupled year over year. \n</p>\n<p>\n  Brisbane, Calif.-based Vera Therapeutics said Saturday evening the phase 2b trial showed stabilized kidney function through 96 weeks of long-term follow-up in patients with the chronic kidney disease that occurs when the protein IgA builds up in the kidneys. \n</p>\n<p>\n  \"The stabilization of kidney function through two years -- the longest duration of data among B cell modulators to date -- positions atacicept as a potential best- and first-in-class treatment option for patients with IgAN,\" said Chief Executive Marshall Fordyce. \n</p>\n<p>\n  Fordyce said the company plans to announce topline results from the phase 3 trial in the second quarter of 2025, and apply for a biologics license application from the Food and Drug Administration later in the year. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Jasmine Li at jasmine.li@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 28, 2024 10:31 ET (14:31 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vera Therapeutics Shares Climb 14% on Positive Results in Kidney Disease Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVera Therapeutics Shares Climb 14% on Positive Results in Kidney Disease Study\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2024-10-28 22:31</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Jasmine Li \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of Vera <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> rose after trial results for its atacicept treatment showed potential to prevent kidney failure in patients with immunoglobulin A nephropathy. \n</p>\n<p>\n  The biotechnology company's stock climbed 14.18% in Monday morning trading. Shares have more than quadrupled year over year. \n</p>\n<p>\n  Brisbane, Calif.-based Vera Therapeutics said Saturday evening the phase 2b trial showed stabilized kidney function through 96 weeks of long-term follow-up in patients with the chronic kidney disease that occurs when the protein IgA builds up in the kidneys. \n</p>\n<p>\n  \"The stabilization of kidney function through two years -- the longest duration of data among B cell modulators to date -- positions atacicept as a potential best- and first-in-class treatment option for patients with IgAN,\" said Chief Executive Marshall Fordyce. \n</p>\n<p>\n  Fordyce said the company plans to announce topline results from the phase 3 trial in the second quarter of 2025, and apply for a biologics license application from the Food and Drug Administration later in the year. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Jasmine Li at jasmine.li@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 28, 2024 10:31 ET (14:31 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2478482623","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2478482623","pubTimestamp":1730125860,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Vera Therapeutics rose after trial results for its atacicept treatment showed potential to prevent kidney failure in patients with immunoglobulin A nephropathy.The biotechnology company's stock climbed 14.18% in Monday morning trading. Shares have more than quadrupled year over year.Brisbane, Calif.-based Vera Therapeutics said Saturday evening the phase 2b trial showed stabilized kidney function through 96 weeks of long-term follow-up in patients with the chronic kidney disease that occurs when the protein IgA builds up in the kidneys.\"The stabilization of kidney function through two years -- the longest duration of data among B cell modulators to date -- positions atacicept as a potential best- and first-in-class treatment option for patients with IgAN,\" said Chief Executive Marshall Fordyce.Fordyce said the company plans to announce topline results from the phase 3 trial in the second quarter of 2025, and apply for a biologics license application from the Food and Drug Adm","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","BK4588":"碎股","BK4539":"次新股","BK4139":"生物科技","LENZ":"Therapeutics","VERA":"Vera Therapeutics, Inc."},"translate_title":"肾脏疾病研究取得积极结果，Vera Therapeutics股价上涨14%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VERA":1,"LENZ":1},"content_text":"By Jasmine Li \n\n\n \n\n\n  Shares of Vera Therapeutics rose after trial results for its atacicept treatment showed potential to prevent kidney failure in patients with immunoglobulin A nephropathy. \n\n\n  The biotechnology company's stock climbed 14.18% in Monday morning trading. Shares have more than quadrupled year over year. \n\n\n  Brisbane, Calif.-based Vera Therapeutics said Saturday evening the phase 2b trial showed stabilized kidney function through 96 weeks of long-term follow-up in patients with the chronic kidney disease that occurs when the protein IgA builds up in the kidneys. \n\n\n  \"The stabilization of kidney function through two years -- the longest duration of data among B cell modulators to date -- positions atacicept as a potential best- and first-in-class treatment option for patients with IgAN,\" said Chief Executive Marshall Fordyce. \n\n\n  Fordyce said the company plans to announce topline results from the phase 3 trial in the second quarter of 2025, and apply for a biologics license application from the Food and Drug Administration later in the year. \n\n\n \n\n\n  Write to Jasmine Li at jasmine.li@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 28, 2024 10:31 ET (14:31 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}